Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis
The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Abstract
The current systematic review and meta-analysis examined the effect of racemic ketamine or esketamine on suicidal ideation in individuals with uni- or bipolar depression. We searched the MEDLINE, Embase, Central, PsycINFO, and Web of Science databases to identify randomized controlled trials that examined the effect of racemic ketamine or esketamine monotherapy on suicidal ideation (SI) in individuals with uni- or bipolar depression. The two monotherapies were compared; the primary outcome was the rate of remission of SI, and the secondary outcome was the SI score. The risk ratio was used as an effect size measure for binary variables, while the standardized mean difference was used as an effect size measure for continuous variables. Our meta-analysis included 13 randomized controlled trials involving 1,1109 individuals with uni- or bipolar depression. Patients receiving racemic ketamine monotherapy had a significantly higher acute SI remission rate than those receiving placebo or midazolam (RR = 2.06, 95% CI 1.47 to 2.91, P < 0.0001). Racemic ketamine also led to significantly lower SI scores than placebo or midazolam (SMD = -0.36, 95% CI -0.71 to -0.01, P = 0.04). The evidence for the treatment of SI with esketamine was inconsistent. The pooled effect sizes for long-term anti-SI effects did not reveal significant differences between therapies. Our study indicated the efficacy of racemic ketamine monotherapy for rapidly and transiently reducing SI in individuals with uni- or…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there is no compelling evidence that esketamine prevents suicide or reduces suicidal ideation or behavior [15, 16].”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We measured heterogeneity using the Chi-square test and I 2 value, and I 2 > 50% and P values ≤ 0.10 indicated significant heterogeneity [ 33].”
InfluentialRoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“We used Version 2 of the Cochrane risk-of-bias tool for ran - domized trials (RoB 2) to assess the included studies for risk of bias [ 31].”
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“The remission of SI was based on the following criteria: a C-SSRS-SI score = 0, an SSI score ≤ 3, or a MADRS-SI score = 0 [ 28–30].”
Methods for the thematic synthesis of qualitative research in systematic reviews
Thomas, J., & Harden, A. (2008) · BMC Medical Research Methodology · doi:10.1186/1471-2288-8-45 · Cited by 9,312
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Assessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419 · cited 1×
“The BSS and SSI assess SI [ 68, 69 ].”
Suicide Prevention Strategies: A Systematic Review
Mann, J. J., Apter, A., Bertolote, J., Beautrais, A., Currier, D., Haas, A., Hegerl, U., Lonnqvist, J., Malone, K., Marusic, A., et al. (2005) · JAMA · doi:10.1001/jama.294.16.2064 · Cited by 2,852 · cited 1×
“However, there are risks associated with ECT, including anesthesia-related complications and cognitive side effects, and current evidence is based on small sample sizes with methodological limitations [ 13, 14 ].”
Suicide prevention strategies revisited: 10-year systematic review
Zalsman, G., Hawton, K., Wasserman, D., van Heeringen, K., Arensman, E., Sarchiapone, M., Carli, V., Höschl, C., Barzilay, R., Balazs, J., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30030-x · Cited by 1,765
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 1×
“Ketamine is an ionotropic glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist and is a racemic mixture of two enan - tiomers: arketamine and esketamine [ 20 ].”
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 3×
“Three of the included studies examined the effects of racemic ketamine on bipolar depression [ 37, 42, 48].”
Clinical correlates of inpatient suicide
Busch, K. A., Fawcett, J., & Jacobs, D. G. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0105 · Cited by 750 · cited 1×
“In actual clinical practice, the peak of suicidal behavior in individuals with major depres - sion is not necessarily at the most severe stage of the illness, but rather in the recovery phase [ 65, 66 ].”
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696 · cited 1×
“Several recent meta-analyses found evidence supporting the beneficial effect of racemic ketamine on SI within hours of administration [ 18, 22 ].”
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009) · BMJ · doi:10.1136/bmj.b2880 · Cited by 609
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605 · cited 1×
“Additionally, although esket - amine has a higher affinity for NMDA receptors and offers a more convenient administration method, there is no evidence to suggest that it is superior to ketamine in reducing suicidal ideation [ 53, 54 ].”
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576 · cited 2×
“6 Forest plots of ( A ) remission rate of suicidal ideation and ( B ) score on the suicidal ideation scale after more than 2 weeks on racemic ket - amine monotherapy benefits of ketamine are unclear [ 25 ].”
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520 · cited 1×
“Additionally, although esket - amine has a higher affinity for NMDA receptors and offers a more convenient administration method, there is no evidence to suggest that it is superior to ketamine in reducing suicidal ideation [ 53, 54 ].”
Noyes, J., Booth, A., Flemming, K., Garside, R., Harden, A., Lewin, S., Pantoja, T., Hannes, K., Cargo, M., & Thomas, J. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.06.020 · Cited by 480 · cited 1×
“A qualitative systematic review was performed to ana - lyze RCTs that did not provide sufficient data for meta-anal - ysis [ 35, 36].”
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440 · cited 1×
“Some first-line antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), can induce suicidal thoughts, self-harm, and suicide in certain individuals at the start of treatment [ 8, 9 ].”
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433 · cited 1×
“Another study comparing the efficacy and safety of four different doses of racemic ketamine with midazolam found no anti-SI benefit at the different doses of racemic ketamine compared with midazolam [ 64].”
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418 · cited 2×
“Eight trials were included in the meta-analysis, and the other 5 studies [ 39, 41, 44, 48, 49 ] were only included in the qualitative analysis because their data were not available.”
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408 · cited 1×
“One study comparing the therapeutic effects of ketamine and esketamine for depression showed that the antidepressant effects of ketamine and escitalopram appear to be similar [ 59, 60].”
Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m13191 · Cited by 376 · cited 2×
“Eight trials were included in the meta-analysis, and the other 5 studies [ 39, 41, 44, 48, 49 ] were only included in the qualitative analysis because their data were not available.”
Price, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S. Z., Soleimani, L., Charney, D. S., Foulkes, A. L., & Mathew, S. J. (2014) · Depression and Anxiety · doi:10.1002/da.22253 · Cited by 345
Sterne, J. A. C., Becker, B. J., & Egger, M. (2005) · Publication Bias in Meta‐Analysis · doi:10.1002/0470870168.ch5 · Cited by 341 · cited 1×
“Publication bias was assessed using funnel plots [ 34].”
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335 · cited 1×
“Race - mic ketamine consists of two enantiomers, S-ketamine and R-ketamine, and different formulations of ketamine exhibit varying affinities and potencies for the NMDA receptor, and therefore leading to different antidepressant and anti-suicidal effects [ 58 ].”
Association between completed suicide and bipolar disorder: A systematic review of the literature
Plans, L., Barrot, C., Nieto, E., Rios, J., Schulze, T. G., Papiol, S., Mitjans, M., Vieta, E., & Benabarre, A. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.054 · Cited by 269
The genetics of bipolar disorder
Gordovez, F. J. A., & McMahon, F. J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0634-7 · Cited by 262
Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202 · cited 1×
“Several recent meta-analyses found evidence supporting the beneficial effect of racemic ketamine on SI within hours of administration [ 18, 22 ].”
Abbar, M., Demattei, C., El-Hage, W., Llorca, P.-M., Samalin, L., Demaricourt, P., Gaillard, R., Courtet, P., Vaiva, G., Gorwood, P., et al. (2022) · BMJ · doi:10.1136/bmj-2021-067194 · Cited by 181
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179
Andrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f11738 · Cited by 178 · cited 1×
“Furthermore, repeated infusions may continue to enhance symptoms [ 24, 55].”
Grunebaum, M. F., Ellis, S. P., Keilp, J. G., Moitra, V. K., Cooper, T. B., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12487 · Cited by 174 · cited 2×
“Three of the included studies examined the effects of racemic ketamine on bipolar depression [ 37, 42, 48].”
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174 · cited 1×
“Notably, racemic ketamine can rapidly and transiently improve depressive symptoms and SI, which has attracted increasing attention in recent years [ 16–19].”
Antidepressants and suicide: what is the balance of benefit and harm
Gunnell, D., & Ashby, D. (2004) · BMJ · doi:10.1136/bmj.329.7456.34 · Cited by 151 · cited 1×
“Therefore, patients taking these medications are at an increased risk for suicidal thoughts and depressive symptoms before reaching maximum anti - depressant efficacy, which typically takes several weeks [ 10, 11 ].”
Phillips, J. L., Norris, S., Talbot, J., Hatchard, T., Ortiz, A., Birmingham, M., Owoeye, O., Batten, L. A., & Blier, P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0570-x · Cited by 139 · cited 2×
“Repeated-dose studies have also shown that reductions in SI may persist for up to six weeks [ 24 ].”
Kliem, S., Lohmann, A., Mößle, T., & Brähler, E. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1559-9 · Cited by 138 · cited 1×
“The BSS and SSI assess SI [ 68, 69 ].”
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134
Ionescu, D. F., Swee, M. B., Pavone, K. J., Taylor, N., Akeju, O., Baer, L., Nyer, M., Cassano, P., Mischoulon, D., Alpert, J. E., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10056 · Cited by 126 · cited 1×
“Previous studies have shown that a single infusion of racemic ketamine can be used for short-term treatment of SI, with benefits last - ing up to one week [ 23 ].”
Li, X., Mu, F., Liu, D., Zhu, J. L., Yue, S., Liu, M., Liu, Y., & Wang, J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.01.103 · Cited by 126 · cited 1×
“People with affective disorders are at especially high risk of SI and suicidal behaviors [ 2, 3]: up to two-thirds of those who die by suicide have major depressive disorder (MDD) [ 4, 5], and up to 20% of individuals with bipolar disorder (BD) have reported SI [ 6, 7 ].”
Xiong, J., Lipsitz, O., Chen-Li, D., Rosenblat, J. D., Rodrigues, N. B., Carvalho, I., Lui, L. M. W., Gill, H., Narsi, F., Mansur, R. B., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.038 · Cited by 124
Suicidal behaviour during different phases of bipolar disorder
Valtonen, H. M., Suominen, K. H., Mantere, O., Leppämäki, S., Arvilommi, P., & Isometsä, E. T. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.05.033 · Cited by 123 · cited 1×
“Individuals with BD are also prone to suicide after experiencing a consid - erable mood drop from manic episodes to depression [ 67].”
Rönnqvist, I., Nilsson, F. K., & Nordenskjöld, A. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.16589 · Cited by 113
Möller, H., Baldwin, D. S., Goodwin, G. M., Kasper, S. F., Okasha, A., Stein, D. J., Tandon, R., Versiani, M., & Pharmacopsychiatry, T. W. S. O. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-3002-1 · Cited by 103
Braun, C., Bschor, T., Franklin, J., & Baethge, C. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442293 · Cited by 103 · cited 1×
“Although tradi - tional antidepressants have some anti-suicidal effects, their slow onset of action increases the risk of suicide at the early stages of treatment [ 51, 52 ].”
Ceban, F., Rosenblat, J. D., Kratiuk, K., Lee, Y. L., Rodrigues, N. B., Gill, H., Subramaniapillai, M., Nasri, F., Lui, L. M. W., Lipsitz, O., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00846-5 · Cited by 102
Zheng, W., Cai, D.-B., Xiang, Y.-Q., Zheng, W., Jiang, W.-L., Sim, K., Ungvari, G. S., Huang, X., Huang, X.-X., Ning, Y.-P., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.002 · Cited by 99 · cited 1×
“Previous studies on the antidepressant effects of ketamine suggest that the route of admin - istration, whether oral, intranasal, or intravenous routes, may not significantly impact its efficacy [ 61, 62].”
Domany, Y., Shelton, R. C., & McCullumsmith, C. B. (2020) · Depression and Anxiety · doi:10.1002/da.22975 · Cited by 84 · cited 1×
“A previous study revealed that intravenous racemic ketamine infusion at 0.2 mg/kg has a more rapid anti-suicidal effect than pla - cebo [ 63 ].”
InfluentialKetamine for Depression, 3: Does Chirality Matter?: (Clinical and Practical Psychopharmacology)
Andrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f11681 · Cited by 78 · cited 1×
“One study comparing the therapeutic effects of ketamine and esketamine for depression showed that the antidepressant effects of ketamine and escitalopram appear to be similar [ 59, 60].”
The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database
Jiang, Y., Du, Z., Shen, Y., Zhou, Q., & Zhu, H. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01732-5 · Cited by 74 · cited 1×
“Additionally, research has indicated that the esketamine has relatively specific adverse reactions, especially, the occurrence of suicidal thoughts and suicide attempts tends to be relatively higher after using esketamine [ 72 ].”
Miola, A., Dal Porto, V., Tadmor, T., Croatto, G., Scocco, P., Manchia, M., Carvalho, A. F., Maes, M., Vieta, E., Sambataro, F., et al. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13351 · Cited by 73 · cited 1×
“People with affective disorders are at especially high risk of SI and suicidal behaviors [ 2, 3]: up to two-thirds of those who die by suicide have major depressive disorder (MDD) [ 4, 5], and up to 20% of individuals with bipolar disorder (BD) have reported SI [ 6, 7 ].”
Su, T., Li, C., Lin, W., Wu, H.-J., Tsai, S., Bai, Y., Mao, W., Tu, P., Chen, L., Li, W., et al. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad014 · Cited by 66
Antidepressants and Suicide Risk: A Comprehensive Overview
Pompili, M., Serafini, G., Innamorati, M., Ambrosi, E., Giordano, G., Girardi, P., Tatarelli, R., & Lester, D. (2010) · Pharmaceuticals · doi:10.3390/ph3092861 · Cited by 53 · cited 1×
“Therefore, patients taking these medications are at an increased risk for suicidal thoughts and depressive symptoms before reaching maximum anti - depressant efficacy, which typically takes several weeks [ 10, 11 ].”
Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence
Andrade, C. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19f12820 · Cited by 49 · cited 1×
“Notably, racemic ketamine can rapidly and transiently improve depressive symptoms and SI, which has attracted increasing attention in recent years [ 16–19].”
Can a Framework Be Established for the Safe Use of Ketamine?
Freedman, R., Brown, A. S., Cannon, T. D., Druss, B. G., Earls, F. J., Escobar, J. I., Hurd, Y. L., Lewis, D. A., López‐Jaramillo, C., Luby, J. L., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030290 · Cited by 48 · cited 1×
“However, it is important to note that the antidepressant effect of ketamine would diminish with repeated adminis - tration and may even lead to ketamine addiction [ 56].”
Psychotic depression and deaths due to suicide
Paljärvi, T., Tiihonen, J., Lähteenvuo, M., Tanskanen, A. J., Fazel, S., & Taipale, H. T. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.10.035 · Cited by 48 · cited 1×
“People with affective disorders are at especially high risk of SI and suicidal behaviors [ 2, 3]: up to two-thirds of those who die by suicide have major depressive disorder (MDD) [ 4, 5], and up to 20% of individuals with bipolar disorder (BD) have reported SI [ 6, 7 ].”
Nikayin, S., Rhee, T. G., Cunningham, M. E., de Fontnouvelle, C. A., Ostroff, R. B., Sanacora, G., & Wilkinson, S. T. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.1074 · Cited by 45 · cited 1×
“…studies and small-sample RCTs comparing the anti-SI effects of ketamine and esketamine in psychiatric disorders, there remains a lack of prospective and head-to-head studies specifically evaluating the anti-SI effects of ketamine and esketamine in individuals with MDD or BD [ 49, 57 ].”
Feeney, A., Hock, R. S., Freeman, M. P., Flynn, M., Hoeppner, B. B., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., Mathew, S. J., DeBattista, C., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.024 · Cited by 42 · cited 1×
“Due to differences in follow-up times and dosages, we excluded Feeney et al., 2021, and performed a sensitivity analysis comparing the efficacy of racemic ketamine to mid - azolam.”
Su, M. ‐., Chen, H. ‐., Lu, M. ‐., Feng, J., Chen, I. ‐., Wu, C. ‐., Chang, S. ‐., & Kuo, P. ‐. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12834 · Cited by 38
Vieira, F., Correia‐Melo, F. S., Santos‐Lima, C., Souza‐Marques, B., Leal, G. C.-G., Jesus‐Nunes, A. P., Mello, R. P., Caliman‐Fontes, A. T., Bandeira, I. D., Marback, R. F., et al. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.12.011 · Cited by 34 · cited 4×
“Ultimately, 13 randomized clinical trials [ 37–49] met the inclusion criteria for the systematic review.”
InfluentialAhmed, G. K., Elserogy, Y., Elfadl, G. M. A., Abdelsalam, K. G., & Ali, M. A. S. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.005 · Cited by 31
The Effect of Ketamine on Electrophysiological Connectivity in Major Depressive Disorder
Nugent, A. C., Ballard, E. D., Gilbert, J. R., Tewarie, P. K., Brookes, M. J., & Zarate, C. A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00519 · Cited by 30 · cited 1×
“Previous studies on the antidepressant effects of ketamine suggest that the route of admin - istration, whether oral, intranasal, or intravenous routes, may not significantly impact its efficacy [ 61, 62].”
Horon, R., McManus, T., Schmollinger, J., Barr, T., & Jimenez, M. M. (2012) · Suicide and Life-Threatening Behavior · doi:10.1111/j.1943-278x.2012.00124.x · Cited by 27
Are Patients With Depression at Heightened Risk of Suicide as They Begin to Recover?
Mittal, V., Brown, W. A., & Shorter, E. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.3.384 · Cited by 26
FDA approves esketamine treatment for MDD, suicidal ideation
Canady, V. A. (2020) · Mental Health Weekly · doi:10.1002/mhw.32471 · Cited by 26 · cited 1×
“Esketamine nasal spray is the only FDA-approved drug for the treatment of MDD in adults with acute SI or suicidal behavior [ 21].”
Luccarelli, J., Humphrey, D., McCoy, T. H., Henry, M., Mueller, M., & Seiner, S. J. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13603 · Cited by 8
Cited by
Mathai, D. S., Cluck, M., Aslam, A. M., Amato, E., Azam, A., Banov, M., Barrett, K. A., Bonnett, C. J., Feifel, D., Grundmann, N., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121970 · Cited by 7
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04435-x · Cited by 6
“However, there is no compelling evidence that esketamine prevents suicide or reduces suicidal ideation or behavior [15, 16].”
Suicidal crisis: first regulatory approval of IV racemic ketamine
Jollant, F., Abbar, M., & Tayeb, A. E. K. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00594-5 · Cited by 4
Zhao, M., Yang, J., & Hashimoto, K. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02066-0 · Cited by 2
Wilkowska, A., & Cubała, W. J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-01958-5
Metadata
- Authors
- Li, J., Ma, L., Sun, H., Li, M., Cao, Y., Peng, Y., & Xu, J.
- Affiliations
- West China Hospital of Sichuan University (CN)
- Jena University Hospital (DE)
- Corresponding author
- Xu, Jiajun
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2024-10-09
- Volume
- 275
- Issue
- 5
- Pages
- 1359-1371
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- OpenAlex
- W4403243821
- Cited by
- 5
- References
- 71
- Citations by year
- 2026: 2 · 2025: 3
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- racemic ketamine, esketamine, suicidal ideation, major depressive disorder, bipolar depression, monotherapy, midazolam, remission, rapid-acting antidepressants
- MeSH terms
- Antidepressive Agents, Bipolar Disorder, Humans, Ketamine, Randomized Controlled Trials as Topic, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.